Skeletal muscle metabolism as a target for drug therapy in peripheral arterial disease

Vascular Medicine

Volumn 1, Issue 1, 1996, Pages 55-59

  Brass, Eric P ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

acylcarnitine; enzymes; metabolism; mitochondria; peripheral arterial disease

Indexed keywords

ACYLCARNITINE; GLYCOGEN;

ATHEROSCLEROSIS; CONFERENCE PAPER; HUMAN; LIMB ISCHEMIA; MITOCHONDRION; PRIORITY JOURNAL; AEROBIC METABOLISM; ARTICLE; ENERGY YIELD; ENZYME ACTIVITY; EXERCISE; FUNCTIONAL STATUS; GLYCOGEN MUSCLE LEVEL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; LEG; MUSCLE METABOLISM; NUCLEAR MAGNETIC RESONANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REPERFUSION INJURY; RESPIRATORY CHAIN; SKELETAL MUSCLE;

EID: 0029992034     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9600100110     Document Type: Conference Paper

References (40)

1. Karmazyn M. Ischemic and reperfusion injury in the heart. Cellular mechanisms and pharmacological interventions. Can J Physiol Pharmocol 1991; 69: 719-30.
2. Piper HM, Noll T, Siegmund B. Mitochondrial function in the oxygen depleted and reoxygenated myocardial cell. Cardiovasc Res 1994; 28: 1-5.
3. Zheng X, Shoffner JM, Voljavec AS, Wallace DC. Evaluation of procedures for assaying oxidative phosphorylation enzyme activities in mitochondrial myopathy muscle biopsies. Biochim Biophys Acta 1990; 1019: 1-10.
4. Krahenbuhl S, Chang M, Brass EP, Hoppel CL. Decreased activities of ubiquinol: ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c:oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin [c-lactam]-induced methylmalonic aciduria. J Biol Chem 1991; 266: 20998-1003.
5. Bandy B, Davison AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med 1990; 8: 523-39.
6. Gunter TE, Gunter KK, Sheu S-S, Gavin CE. Mitochondrial calcium transport: physiological and pathological relevance. Am J Physiol 1994; 267: C313-C339.
7. 2. J Appl Physiol 1990; 68: 833-12.
8. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284: 1-13.
9. Kotaka K, Miyazaki Y, Ogawa K, Satake T, Sugiyama S, Ozawa T. Reversal of ischemia-induced mitochondrial dysfunction after coronary reperfusion. J Mol Cell Cardiol 1982; 14: 223-31.
10. Piper HM, Sezer O, Schleger M, Schwartz P, Hutter JF, Spieckermann PG. Development of ischemia-induced damage in defined mitochondrial subpopulations. J Mol Cell Cardiol 1985; 17: 885-96.
11. Corral-Debrinski M, Stepien G, Shoffner JM, Lott MT, Kanter K, Wallace DC. Hypoxemia is associated with mitochondrial DNA damage and gene reduction. JAMA 1991; 266: 1812-16.
12. Pernew B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstruction at different levels. Scand J Clin Invest 1968; 21: 277-87.
13. Hiatt WR, Nawaz D, Regensteiner JG, Hossack KF. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil 1988; 12: 525-32.
14. Hiatt WR, Nawaz D, Brass EP. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987; 62: 2383-87.
15. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appl Physiol 1984; 56: 831-38.
16. Janssen E, Johansson J, Sylven C, Kaijser L. Calf muscle adaptation in intermittent claudication. Side differences in muscle metabolic characteristics in patients with unilateral arterial disease. Clin Physiol 1988; 8: 17-29.
17. Lundgren F, Dahllof A-G, Schersten T, Bylund-Fellenius A-C. Muscle enzyme adaptation in patients with peripheral arterial insufficiency: spontaneous adaptation, effect of different treatments and consequences on walking performance. Clin Sci 1988; 77: 485-93.
18. Bylund AC, Hammarsten J, Holm J, Schersten T. Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency. Eur J Clin Invest 1976; 6: 425-29.
19. Regensteiner JG, Wolfel EE, Brass EP et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease Circulation 1993; 87: 415-21.
20. England JD, Regensteiner JG, Ringel SP, Carry MR, Hiatt WR. Muscle denervation in peripheral arterial disease. Neurology 1992; 42: 998-99.
21. Hiatt WR, Regensteiner JG, Wolfel EE, Curry MR, Brass EP. Manuscript in preparation.
22. Bremer J. Carnitine - metabolism and functions. Physiol Rev 1983; 63: 1420-80.
23. Hoppel CL. Determination of carnitine. In: Hammes FA ed. Techniques in diagnostic human biochemical genetics. New York: Wiley-Liss, 1991: 309-26.
24. Hiatt WR, Wolfel EE, Regensteiner JG, Brass EP. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol 1992; 73: 346-53.
25. Brass EP, Hiatt WR. Carnitine metabolism during exercise. Life Sci 1994; 54: 1383-93.
26. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81: 602-609.
27. 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise. NMR Biomed 1993; 6: 302-10.
28. DiDonato S, Frerman FE, Rimoldi M, Rinaldo P, Taroni F, Wiesmann VN. Systemic carnitine deficiency due to lack of electron transfer flavoprotein:ubiquinone oxidoreductase. Neurology 1986; 36: 957-63.
29. Campeo Y, Huertes R, Lorenzo G et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1990; 16: 150-53.
30. Robinson BH. Lactic acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D eds. The metabolic basis of inherited disease. New York: McGraw-Hill Information Services, 1989, 869-88.
31. Park R, Arief AI. Treatment of lactic acidosis with dichloroacetate in dogs. J Clin Invest 1982; 70: 853-62.
32. Carraro F, Klein S, Rosenblatt JI, Wolfe RE. Effect of dichloroacetate on lactate concentration in exercising humans. J Appl Physiol 1989; 66: 591-97.
33. Thadani W, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 1994; 90: 726-84.
34. Bevan EG, Walker PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992; 2: 125-36.
35. Moody AP, Al-Khaffaf HS, Lehert P, Harris FL, Charlesworth D. An evaluation of patient with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 (suppl 3): S44-S47.
36. Brass EP. Overview of coenzyme A metabolism and its role in cellular toxicity. Chem Biol Interact 1994; 90: 203-14.
37. Broderick TL, Quinney A, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993; 87: 932-81.
38. Brevetti G, Chiariello M, Ferulano G et al. Increases in walking distances in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767-73.
39. Brevetti G, Perna S, Sabba C et al. Superiority of L-propionyl carnitine vs. L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251-55.
40. Davis EJ, Spydevold O, Bremer J. Pyruvate carboxylase and propionyl-CoA carboxylase as analplerotic enzymes in skeletal muscle mitochondria. Eur J Biochem 1980; 110: 255-62.